Nephrology Medical News about Eculizumab

Your Unread Messages

See All

Tracy Hampton, PhD

FDA Update

New Ovarian Cancer Test Guides Surgical Decisions

Roberta Buell, MBA
Congress Proposes SGR Fix

Dorothy J. Schirf, MD

Technology Advances

Radiosurgery Trial Sparks Optimism for Early Lung Cancer

Sara Hartley

Cancer Science

Using Embryonic Stem Cells to Test Breast Cancer Genes

See All Messages (38 new messages)

Hello, Suzanne Dixon
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

5. Debunking Myths in the US Healthcare System

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Severe atypical HUS caused by CFH S1191L--case presentation and review of treatment options
Pediatric Nephrology, 11/04/09

De S et al. – Eculizumab, a monoclonal humanized anti–C5 antibody, has recently been shown to be effective and well–tolerated in patients with paroxysmal nocturnal hemoglobinuria by preventing complement–mediated lysis of affected erythrocytes. Treatment of the patient with eculizumab is supported by recent reports on its successful use in two (pediatric and adult) patients with complement–based aHUS.

<< Previous
The Role of the Mammalian Target Of Rapamycin (mTOR) in Renal...

Next >>
Acute post-streptococcal glomerulonephritis in children of French...